Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,351 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glioblastoma, Glioma Clear all
Not yet recruiting Phase 1 Interventional

A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma

NCT07422896
View directory record Official record
Conditions
Glioblastoma
Interventions
B-cell vaccination
Biological
Lead sponsor
Catalina Lee Chang
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 16, 2026, 4:03 PM EDT
Not listed Phase 2 Interventional

MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

NCT02137759
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain
Interventions
Standard Radiation Therapy, Standard Temozolomide, Belinostat
Radiation · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

NCT02017717
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Nivolumab, Bevacizumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

NCT02661282
View directory record Official record
Conditions
Cytomegalovirus Positive, Glioblastoma, Gliosarcoma, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
Interventions
Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, Temozolomide, Therapeutic Conventional Surgery
Biological · Other · Drug + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors

NCT00008086
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
calcitriol, carboplatin
Dietary Supplement · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 16, 2026, 4:03 PM EDT
Not listed Phase 1 Interventional

Phosphorus 32 in Treating Patients With Glioblastoma Multiforme

NCT00004129
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
brachytherapy, phosphorus P32
Radiation
Lead sponsor
Center for Molecular Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Garden City, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

CC-5013 in Treating Patients With Recurrent Glioma

NCT00036894
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 16, 2026, 4:03 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

NCT02876003
View directory record Official record
Conditions
Glioblastoma
Interventions
G-202
Drug
Lead sponsor
GenSpera, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

NCT00005976
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, pyrazoloacridine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
22
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

NCT02968940
View directory record Official record
Conditions
Glioblastoma
Interventions
Avelumab, Hypofractionated radiation therapy (HFRT)
Biological · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM

NCT02202993
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM)
Interventions
Mibefradil with Radiation
Drug
Lead sponsor
Cavion, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme

NCT02017249
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
arginine in powder form, Silica and cellulose placebo powder
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 16, 2026, 4:03 PM EDT
Withdrawn Phase 1 Interventional

Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

NCT00734864
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioma
Interventions
enzyme-inducing anti-epileptic drugs
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 16, 2026, 4:03 PM EDT
Terminated Phase 1 Interventional

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

NCT03332355
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
PAC-1 Compound
Drug
Lead sponsor
Vanquish Oncology, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

NCT00002752
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
iodine I 131 monoclonal antibody 81C6
Radiation
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 16, 2026, 4:03 PM EDT
Terminated Not applicable Interventional Results available

Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)

NCT01925573
View directory record Official record
Conditions
RECURRENT GLIOBLASTOMA, Brain Tumor
Interventions
Optune(NOVOTTF-100A)
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
22 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

NCT04704154
View directory record Official record
Conditions
Solid Tumors
Interventions
Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 16, 2026, 4:03 PM EDT
Completed No phase listed Observational

The Registry of Oncology Outcomes Associated With Testing and Treatment

NCT04028479
View directory record Official record
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
Diagnostic Test · Drug · Other
Lead sponsor
Taproot Health
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Idaho Falls, Idaho • Laredo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

NCT00074646
View directory record Official record
Conditions
Glioblastoma, Malignant Gliomas
Interventions
CC-8490
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2007 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma

NCT00005951
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse

NCT00016991
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gefitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

NCT02573324
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414
Drug · Radiation
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
68
States / cities
Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma

NCT00070525
View directory record Official record
Conditions
Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

A Drug-drug Interaction Study of Avapritinib and Midazolam

NCT04908176
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
Interventions
Avapritinib, midazolam
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 16, 2026, 4:03 PM EDT